This week's Houston innovators to know includes Lenny Saizan of Urban Capital Network, Katie Eick of Rollin' Vets, and Tony Loyd of AECOM. Courtesy photos

Editor's note: This year has made for some pivotal moments for various Houston companies across industries. For some, the pandemic has meant reevaluating their business plans or increased a need for their product or service. For others, social unrest has called for systemic change. Technology emerges for these needs. This week's Houston innovators are addressing these needs with their innovative efforts.

Lenny Saizan, co-founder and managing partner

Lenny Saizan — along with three other Houston innovation leaders — founded Urban Capital Network to increase diversity and inclusion within the venture capital space. Photo via urbancapitalnetwork.com

While venture capital firms usually operate in a similar structure, Lenny Saizan and his co-founders wanted to set up Urban Capital Network differently in order to "democratize access to premium VC-backed investments," Saizan says. UCN invests into VCs that meet their diversity and inclusion requirements as a limited partner, but then also invests directly into startups as a sort of hybrid investor.

"We take a portion of our proceeds and invest in entrepreneurs of color, and we also donate to nonprofits that provide support resources for those entrepreneurs," Saizan says on this week's episode of the Houston Innovators Podcast. "We're completing the cycle. We find that it's easier to go to a VC and offer to give them money and also help them diversify their investor portfolio."

Saizan shares more about the group in the podcast episode and discusses what they've already accomplished in just a few months. Read more.

Katie Eick, founder of Rollin' Vets

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

Katie Eick founded her mobile vet company in 2016 after years of wanting to be able to provide the type and level of service she has now at Rollin' Vets. While convenience technologies like delivery apps buoyed her company's steady growth, the pandemic really established market need for her business model.

"We were continuously growing slowly — then COVID hit. It really cemented that … all the convenience services are in the forefront of people's minds." Eick tells InnovationMap. "COVID made it clear that this was a necessary service."

Now, she plans to adopt a franchising model and is planning an expansion into San Antonio and Dallas before going national. Read more.

Tony Loyd, vice president at AECOM

Just like Hurricane Harvey, COVID-19 is causing Houstonians to rethink how they operate — and that tech and innovation inversion is opening the door to new opportunities. Courtesy Photo

COVID-19 is affecting the evolution of technology — it's as simple as that, according to Tony Loyd. And it's not the first time — nor the last — that consumer needs affect tech innovation.

"Could COVID-19 be triggering an inversion paradigm? An inversion paradigm puts needs first rather than product first," writes Loyd in a guest column for InnovationMap. "We have experienced many historic technology inversions. Remember when our televisions were air-wave dependent and telephones were tethered to the wall? Because the need evolved for a phone that was mobile, today our TV's are wired, and our telephones are untethered." Read more.

Just like Hurricane Harvey, COVID-19 is causing Houstonians to rethink how they operate — and that tech and innovation inversion is opening the door to new opportunities. Photo via Getty Images

Houston primed for opportunity within the tech inversion caused by the pandemic

Guest column

For has long as I can remember, I had to live near water. That's why I moved to Houston. Recently, new neighbors moved next door from the downtown Galleria area. They loved it there until coronavirus turned shopping habits into stay-at-home habits. The experience led them to recognize they could do just fine without the Galleria-area routine, pivoting instead to a maritime lifestyle.

Could COVID-19 be triggering an inversion paradigm? An inversion paradigm puts needs first rather than product first. We have experienced many historic technology inversions. Remember when our televisions were air-wave dependent and telephones were tethered to the wall? Because the need evolved for a phone that was mobile, today our TV's are wired, and our telephones are untethered.

This technology inversion fundamentally found its way to the individual consumer and transformed entire industries. Houston businesses are responding to a rare COVID-19-induced disruption. Inversions are rare, but when they occur, opportunity follows.

Large infrastructure challenges are normally led by bureaucratic funding processes that result in productized solutions. Hurricane Harvey was a wake-up call to take decisive action to protect decades of private and public investment against future flood events. It was an analogue to removing the board with the nail in it from the driveway to avoid endless tire repairs.

Now, Houston's resilience infrastructure is going through a Hurricane Harvey-induced inversion. The fundamental approach to water management is experiencing a historic reversal which focuses on need rather than a response cycle. Largely dependent on surface run-off systems, Houston experienced a river running through it during Hurricane Harvey. In response, studies and projects are underway to consider a major underground storm drainage system. Water management is fundamentally changing to move stormwater from above ground to below grade, while domestic water is moving away from underground sources to surface supplies, such as lakes. These programs reduce threats to downtown, allowing urbanism and businesses to flourish, simply by addressing a human need in lieu of building another drainage product.

Fortunately for the Houston economy, pre-COVID, quasi-inversion programs already in place to address mobility needs, such as the $7.5 billion METRONext program and $4.8 billion for flood control essentials, are injecting billions of dollars into the local economy. At the federal level, future stimulus funding designed to address infrastructure needs and the economic impact of Coronavirus are likely to follow next year. Consequently, the current Hurricane Harvey, COVID-19 inversion could position Houston to rebound from a time of trial reimagining what a next generation city in the modern age should look like.

Graphic courtesy of AECOM

In fact, infrastructure programs have a long history of creating sustainable jobs and transforming cities. Did you know the River Walk in San Antonio, a downtown centerpiece that thrives today and contributes to thousands of job opportunities, was a construction project born during the Great Depression to address a disastrous flood occurring in the early 1920s? San Antonio architect Robert H. H. Hugman was elected to address a need to save lives and reimagine San Antonio's downtown. The city was altered forever by creating a flood resilience infrastructure that also transformed its city center into a civic gathering place that made San Antonio one of the largest destination cities in Texas.

While technology inversions are occurring more often than before, they are still rare, and each one is very important. Infrastructure inversions that transform cites are even more exceptional. In a COVID-19-induced inversion period, the possibilities are limitless, and the time is now. With programs underway and potential stimulus funding to support additional investment to address city needs, Houston is positioned for something amazing.

------

Tony Loyd is based in Houston and vice president at AECOM.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.